When: Deeper pullback to $147-150 zone

Then: Add up to 30-35% of position size

When: Confirmed close <$154 with volume, OR forward EPS revisions toward $6.50-6.75, OR restructuring charges sustain at $100M+/quarter beyond Q4 FY26

Then: Downgrade to Underweight

When: Early November 2026 print

Then: Monitor FY27 guidance direction, AI-product revenue attribution, restructuring charge trend, net debt trajectory

HOLD with $154 stop; wait for $147-150 zone to add

• ATR expanded 21% in a month to $4.79 — signals stretched tape, not healthy continuation
• 11.36% 30-day run with elevated ATR and MACD at double prior local peak creates high probability of 5-10% pullback within 2-4 weeks
• Historical MACD pattern: +2.81 on June 22, full round-trip to -1.26 by July 20 — "We've already seen this movie"
• Forward P/E of 22.73 is more honest than TTM P/E of 36 (depressed by $93 to $206M in quarterly unusual charges)
• Forward EPS of $7.23 implies 58% growth from current trailing levels — requires near-perfect execution on AspenTech and NI integration
• PEG of 1.83 is not a trap but a warning that stock needs to perform to hold its line
• $18.15B goodwill (43% of total assets) creates multiple compression risk in no-cut regime
• Operating margins at 26.9% — easy gains largely captured; unclear where next 200bps comes from
• $356M buyback acceleration is programmatic capital return, not insider conviction signal
• Oil is both a tailwind (power generation capex) and headwind (cost input for process-industry customers' margins)
• Honeywell's -5% drawdown is contagion risk for EMR, not relative-strength opportunity — sector misses prompt Street to question EMR guidance
• Base rate for industrial companies missing forward EPS guidance is 30-40%; EMR has specific integration noise making guidance path less clean
• A 5-10% EPS miss could deliver 15% drawdown from multiple compression alone — not a tail risk, a probable scenario
• From $164, upside requires everything to go right; downside only requires one thing to slip — unfavorable asymmetry for adding at current levels

→ vs aggressive: Upper Bollinger Band as 'runway' — ignores that ATR expansion to $4.79 signals stretched tape, not healthy trend; upper band is where stops get triggered on reversal

→ vs aggressive: 'Pullbacks won't come' assumption is dangerous — 11.36% run with elevated ATR and MACD peak creates textbook mean-reversion conditions; prior MACD pattern proves this happens even in quality names

→ vs aggressive: Forward P/E of 22.73 is more honest, but paying premium for 'cleanest story in cohort' flips asymmetry — you're paying full price for a story that still has to deliver

→ vs aggressive: 'No Fed cuts is bullish for compounders' frame doesn't apply at 23x forward — EMR has $18.15B goodwill and high multiple; no-cut regime pressures through multiple channel, not earnings

→ vs aggressive: Revenue plateau reframed as margin story ignores where next 200bps of margin comes from at 26.9% — 'easy gains largely captured'; any Q4 margin compression hits from two directions at once

→ vs aggressive: $356M buyback acceleration signals programmatic compliance, not conviction — companies buy back at the top all the time; 'reading conviction where there is only compliance'

→ vs aggressive: Oil as tailwind ignores cost-input headwind — higher oil compresses process-industry customer margins, delaying capex; 'selection bias, not analysis'

→ vs aggressive: Honeywell -5% as relative tailwind misreads institutional desk behavior — HON miss becomes EMR question on Q4 call; 'contagion risk, not relative-strength opportunity'

HOLD

• Hold core position with trailing stop near 154 (10 EMA at 154.78, approximately 2 times ATR below current price)
• Resist adding at 164—current levels don't offer sufficient risk-reward given stretched technicals and premium valuation (forward P/E of 22.73, PEG at 1.83)
• Add incrementally on pullback to 154 to 158 zone (confirmed consolidation entry)
• Consider more meaningful addition at 147 to 150 zone (middle Bollinger Band with uptrend intact)
• Breakout above 165 would represent confirmed breakout opportunity warranting review
• TTM P/E of 36 is depressed by integration charges/goodwill amortization; forward P/E of 22.73 is more relevant
• Forward EPS of 7.23 requires near-perfect execution across integration, software mix-shift, and industrial capex
• Operating margins at 26.9 percent are already premium-tier; next 200 basis points of margin expansion is uncertain
• Revenue trajectory (4.55, 4.85, 4.35, 4.35, 4.56) shows top-line stagnation, creating vulnerability if margins compress in Q4
• Buybacks at 356 million dollars signal mild positive conviction but not definitive insider conviction
• No Fed cuts is a mild headwind on multiple expansion but not existential; EMR's FCF profile provides protection
• Geopolitical/oil effects are roughly neutral to slightly positive for EMR
• Portfolio diversification and position sizing relative to total risk should be considered

→ vs aggressive: Uses survivorship bias framing—selecting setups that survived while ignoring identical setups that rolled over (MACD at plus 2.81 in late June followed by full round-trip to July 20 trough)

→ vs aggressive: Treats momentum and fundamental trajectory as if risks are already priced out; they aren't priced out, they're being ignored

→ vs aggressive: Forward P/E of 22.73 with PEG at 1.83 requires near-perfect execution; 5 percent slip on any assumption creates double whammy of multiple compression and EPS revision

→ vs aggressive: Hasn't fully addressed scenario where margins plateau or compress in Q4 while revenue stays flat, hitting stock from both directions

→ vs aggressive: Buyback argument overreaches—accelerated buybacks signal reasonable valuation, not personal net worth conviction equivalent to insider buying

→ vs aggressive: Oil/geopolitical bullish linkage selection bias underweights second-order margin compression effect on EMR's process industry customers

→ vs conservative: Treats mean reversion as mechanical and foregone conclusion; timing is not precise—pullback may not arrive at 10 EMA at 154.78, stock may trade 170 to 175 first

→ vs conservative: Treats upside as exhausted by risk; it isn't—quality compounders with real cash generation can expand multiple in hawkish regimes

→ vs conservative: Overstates no-cut headwind; EMR at 23 times forward with 18 billion in goodwill and elite FCF margins is not a 35 times SaaS name

→ vs conservative: Revenue plateau point is valid but reframe as margin story is fair up to a point; the right question about 200 basis points margin expansion is acknowledged but timing uncertainty cuts both ways